These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30710686)

  • 1. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
    Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
    Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
    Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.
    Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn JY; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):270-278. PubMed ID: 30292009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
    Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
    Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
    El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
    Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
    Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.
    Holtan SG; Zhang L; DeFor TE; Bejanyan N; Arora M; Rashidi A; Lazaryan A; Kotiso F; Blazar BR; Wagner JE; Brunstein CG; MacMillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1884-1889. PubMed ID: 31128328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
    Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
    Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
    Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
    Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.
    Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Ahmed I; Aljurf M; Askar M; Auletta JJ; Bhatt V; Bredeson C; Chhabra S; Gadalla S; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Inamoto Y; Kitko C; Khandelwal P; MacMillan ML; Majhail N; Marks DI; Mehta P; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Qayed M; Rangarajan H; Ringden O; Saad A; Savani BN; Seo S; Shah A; Shah N; Schultz KR; Solh M; Spitzer T; Szer J; Teshima T; Verdonck LF; Williams KM; Wirk B; Wagner J; Yared JA; Weisdorf DJ
    Blood Adv; 2019 May; 3(9):1441-1449. PubMed ID: 31053571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
    Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
    Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
    Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Agrawal V; Ahmed I; Al-Homsi AS; Aljurf M; Antin JH; Askar M; Auletta JJ; Bhatt VR; Chee L; Chhabra S; Daly A; DeFilipp Z; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Hogan WJ; Inamoto Y; Martino R; Majhail NS; Marks DI; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Rangarajan HG; Ringden O; Saad A; Savani BN; Schoemans H; Seo S; Schultz KR; Solh M; Spitzer T; Storek J; Teshima T; Verdonck LF; Wirk B; Yared JA; Cahn JY; Weisdorf DJ
    J Clin Oncol; 2020 Jun; 38(18):2062-2076. PubMed ID: 32364845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
    Qayed M; Wang T; Hemmer MT; Spellman S; Arora M; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Aljurf M; Ayas M; Bitan M; Cairo M; Choi SW; Dandoy C; Delgado D; Gale RP; Hale G; Frangoul H; Kamble RT; Kharfan-Dabaja M; Lehman L; Levine J; MacMillan M; Marks DI; Nishihori T; Olsson RF; Hematti P; Ringden O; Saad A; Satwani P; Savani BN; Schultz KR; Seo S; Shenoy S; Waller EK; Yu L; Horowitz MM; Horan J
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):521-528. PubMed ID: 29155316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
    Inagaki J; Fukano R; Noguchi M; Okamura J
    Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
    Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.